Rxsight Inc

RXST remains locked in a Stage 4 decline with a persistent sequence of lower highs and lower lows, trading below the 50 DMA and 200 DMA. The recent bounce above the 9 EMA/21 EMA offers a clean speculative sell entry in line with the dominant downtrend. No primary patterns support a bullish reversal, so execution should capitalize on resumed weakness while respecting resistance zones. A close above key moving averages would invalidate this bearish posture.

• ↑LAL adjustability enhances clinical outcomes, addressing unmet premium IOL needs.
• ↑Surgeon re-engagement program shows early stabilization in utilization rates.
• ↓Q1 2026 revenue fell 18% YoY to $30.9M; net loss reached $15.9M.